D&D Pharmatech is set to expand its partnerships by presenting the Phase 2 results of Zabopegdutide before executives from global pharmaceutical companies.
The company announced on June 23 that its U.S. subsidiary, Neuraly, has been invited to present at the Shark Tank session of the SOLAR Conference 2026, taking place in San Juan, Puerto Rico, on June 27.
The SOLAR Conference 2026 is a global academic event focused on sharing the latest research and clinical strategies in metabolic liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASH).
The Shark Tank session allows companies to present clinical data and development strategies to executives and key opinion leaders from major pharmaceutical firms, followed by in-depth discussions. Real-time Q&A sessions will validate clinical differentiation and commercial potential.
Experts in the MASH field, including Dr. Majid Nureddin and Dr. Naim Al-Khouri, along with key figures from global big pharma, are expected to participate as panelists.
Adam Bell, Vice President of Translational Medicine and Regulatory Affairs at Neuraly, will present the biopsy results from the Phase 2 trial of Zabopegdutide and discuss the development strategy.
Bell will highlight the clinical competitiveness and development potential of Zabopegdutide, aiming to broaden ongoing global partnership discussions and explore various collaboration opportunities.
"This is a significant opportunity to present our clinical data before global experts and big pharma representatives," said D&D Pharmatech CEO Lee Seul-ki. "We will do our utmost to expand future development and global partnership opportunities."
Meanwhile, the company has been in discussions with major U.S. investment banks and consulting firms since mid-2025 to facilitate global technology transfer and strategic partnerships for DD01.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.